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Abstract

The incidence and prevalence of diabetes in youth in the United States is increasing. In
particular, type 2 diabetes mellitus (T2DM) is becoming more common in individuals younger
than 20 years. Nurse practitioners and other primary care providers that see children should be
knowledgeable about the condition and confident in participating in multidisciplinary
management. Screening should begin at age 10 or at puberty, whichever comes first. Providers
should screen all children who are overweight or obese or of Native American, African
American, Latino, Asian American, or Pacific Islander race or ethnicity. Children of these
ethnicities have a greater risk for developing T2DM. Screening and diagnostic tests include
fasting plasma glucose, the oral glucose tolerance test, and hemoglobin A1C. Once T2DM is
diagnosed, management should focus on intensive lifestyle changes and weight loss with dietary
changes and increased physical activity. Initial pharmacological treatment involves an oral
antihyperglycemic agent and/or subcutaneous insulin therapy. Effective management of a child
or adolescent with diabetes involves the creation of a multidisciplinary team consisting of an
endocrinologist, social worker, diabetic educator, dietician, school personnel, psychologist, and
the family. The family should participate in all aspects of care and commit to making lifestyle
changes with the patient. As most youth diagnosed with T2DM are adolescents, they should be
encouraged to practice independent care to enable successful transition to young adulthood.
Providers should practice culturally sensitive care and individualize treatment and management
plans for each patient.
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Type 2 Diabetes Mellitus in the Pediatric Population
Pediatric diabetes mellitus is on the rise. Both type 1 and type 2 are increasing in youth.
The Centers for Disease Control (CDC, 2020) reports that an estimated 210,000 children and
adolescents younger than 20 years old had diabetes by 2018. The SEARCH study is a national,
ongoing study with multiple centers participating in research to discover new information
regarding diabetes and youth. Information from the SEARCH study revealed increasing rates of
diabetes among youth in the United States (US), especially among youth of minority racial and
ethnic groups. From 2001 to 2009, the prevalence of type 1 diabetes mellitus (T1DM) increased
by 21.1% while type 2 diabetes mellitus (T2DM) increased by 30.5% in most age, sex, and race
or ethnicity groups (Dabelea, et al., 2014; Hamman et al., 2014). From 2002 to 2012, the annual
increase in incidence was 1.8% for T1DM and 4.8% for T2DM (Mayer-Davis et al., 2017;
Jensen & Dabelea, 2018). These results provide evidence of the increase of diabetes in youth and
should not be overlooked. In particular, T2DM has become a more common condition in
individuals younger than 20 over the last two decades, likely due to an increase in childhood
obesity. Overweight and obesity are major risk factors for T2DM, and the prevalence and
incidence of pediatric diabetes has increased in association with the rise of childhood obesity
(Arslanian et al., 2018; Galuska et al., 2018; Dabelea et al., 2015; Narasimhan & Weinstock,
2014). Due to the increasing amount of overweight and obese children in the US, nurse
practitioners (NPs) and other primary care providers (PCPs) who care for children should be
aware and knowledgeable of diabetic conditions. The purpose of this article is to discuss the
current screening guidelines, presentation, diagnosis, treatment, and multidisciplinary
management of T2DM in youth.
Background
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T2DM was previously thought to be a chronic disease seen only in adults; however, an
increasing number of youths are developing insulin resistance and being diagnosed as type 2
diabetics. As in adults, T2DM is characterized by insulin resistance rather than an autoimmune
process that leads to the destruction of beta cells. Type 1 diabetics will typically have
autoantibodies present at the time of diagnosis and require insulin treatment to survive (Dabelea
et al., 2015; Barrett, 2016; Xu & Verre, 2018; Zeitler et al., 2018). Type 2 diabetics will not
typically have autoantibodies and will still have the ability to produce insulin despite insulin
resistance and pancreatic beta cell failure. These cellular impairments are likely brought on by
puberty and hormonal changes as well as genetic, environmental, or lifestyle factors, such as
poor diet, lack of physical activity, and overweight or obesity; hence, the increasing rates of both
childhood obesity and diabetes (Dabelea et al., 2015; Barrett, 2016; Arslanian et al., 2018;
Zeitler et al., 2018).
Although there are distinct differences between type 1 and type 2 diabetes, it is important
to note that it has become increasingly difficult to distinguish and diagnose children with the
correct diabetes type. Some children will be asymptomatic or have symptoms attributed to both
types, and it is possible for an overweight or obese child to have T1DM. Moreover, results from
the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study found up
to 9.8% of children with a diagnosis of T2DM to have autoantibodies (Klingensmith et al.,
2010).
More often than not, children with T2DM will be overweight or obese and may already
have other comorbidities related to an increased body mass index (BMI), such as hypertension or
dyslipidemia. Furthermore, these youth are at higher risk for developing complications or other
comorbidities due to diabetes as T2DM in youth leads to a more rapid progression of
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comorbidities and risk for complications as compared to adults and other youth with T1DM
(Dabelea et al., 2015; Barrett, 2016; Xu & Verre, 2018; Zeitler et al., 2018).
Presentation, Screening, and Diagnosis
Children with diabetes can be symptomatic or asymptomatic. Symptomatic children may
present with the classic symptoms of polyuria, polydipsia, and unintentional weight loss,
accompanied with or without nausea, vomiting, and dehydration. Metabolic disturbances,
diabetic ketoacidosis, or hyperosmolar states may also be present at the time of diagnosis. The
American Academy of Pediatrics (AAP) recommends symptomatic children to be tested for
ketosis with either serum or urine ketones and evaluating for ketoacidosis by obtaining a venous
pH level (Copeland et al., 2013). Asymptomatic children may be diagnosed from incidental
findings of screening tests done due to the presence of diabetic risk factors (Klingensmith et al.,
2016; Xu & Verre, 2018). Additional signs or conditions related to insulin resistance include
acanthosis nigricans, hypertension, hyperlipidemia, polycystic ovary syndrome, or small-forgestational-age birth weight (Arslanian et al., 2018).
NPs and other providers should screen all children with risk factors for diabetes as well
as children presenting with signs and symptoms of diabetes. When screening, it is important to
note that the onset of T2DM prior to puberty is rare, and nearly all youth in North America
diagnosed with the condition are overweight or obese (Arslanian et al., 2018). The American
Diabetes Association ([ADA], 2020a) recommends screening to begin at age 10 or at the onset of
puberty, depending on whichever comes first, and if the child is overweight or obese with one or
more of the following factors: a maternal history of diabetes or gestational diabetes mellitus
during the child’s gestation, a family history of T2DM in a first or second degree relative, and
Native American, African American, Latino, Asian American, or Pacific Islander race or
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ethnicity. It should be noted that children of these ethnicities have a higher risk for developing
T2DM (Mayer-Davis et al., 2014; Jensen & Dabelea, 2018).
The ADA (2020b) and International Society of Pediatric and Adolescent Diabetes
([ISPAD], 2018) recommend three different tests for diabetes screening: fasting plasma glucose
(FPG), oral glucose tolerance test (OGTT), and hemoglobin A1C (HbA1c). These tests may be
used for both screening and diagnosis. Diagnosis will require two abnormal tests results from the
same samples or two separate samples. If two different tests are performed (i.e. HbA1c and
FPG), and both indicate diabetes, this can also confirm the diagnosis (ADA, 2020b).
FPG is a convenient one-time blood draw. It does require fasting for at least 8 hours prior
to testing.
The OGTT requires fasting, as well as additional time to perform the test. Providers
should follow the World Health Organization (WHO) guidelines and use a glucose load of
1.75mg/kg (or a maximum of 75 grams) anhydrous glucose dissolved in water. After 2 hours of
ingesting the solution, plasma glucose should be checked.
HbA1c is also a convenient one-time blood draw and does not require fasting or
additional time to perform the test. Additionally, this test may be more sensitive and specific for
detecting diabetes when compared to the OGTT (Ehehalt et al., 2017). All HbA1c tests should be
performed in a laboratory using a method that is National Glycohemogloblin Standardization
Program (NGSP) certified and standardized to the Diabetes Control and Complications Trial
(DCCT) assay for reliable and accurate results. Despite the benefits and standardization of the
test, there are multiple factors that can affect a child’s HgbA1c level including ethnicity, age,
medications, hemoglobinopathies, and disorders that affect red blood cell turnover (Vajravelu &
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Lee, 2018). Providers suspecting diabetes should keep this in mind when interpreting HbA1c
results.
The ADA (2020b) criteria for the diagnosis of prediabetes and diabetes are the same for
children, adolescents, and adults. The criteria for diagnosing prediabetes includes the following:
HbA1c 5.7% to 6.5%, FPG greater than or equal to 100 mg/dL but less than 126 mg/dL, and 2hour plasma glucose greater than or equal to 140 mg/dL but less than 200 mg/dL during an
OGTT. The criteria for diagnosing diabetes is HbA1c greater than or equal to 6.5%, FPG greater
than or equal to 126 mg/dL, 2-hour plasma glucose greater than or equal to 200 mg/dL during an
OGTT, or in a patient with classic symptoms of hyperglycemia a random plasma glucose greater
than 200 mg/dL. Providers considering a diagnosis of T2DM for their patients should also obtain
a pancreatic autoantibodies panel to further confirm the diagnosis and exclude T1DM. For
providers screening at-risk children, tests should be repeated every 3 years at a minimum and
more frequently if the child has an increasing BMI (ADA, 2020b).
Treatment
The initial treatment of T2DM should involve therapeutic lifestyle changes. In addition to
dietary changes, adding physical exercise, and education, the AAP recommends that all children
and adolescents start metformin at the time of diagnosis (Copeland et al., 2013). The ADA
(2020a) also recommends that those with a HbA1c less than 8.5% and no acidosis or ketosis be
started on metformin. Metformin is considered the first-line pharmacological treatment for youth
with T2DM and was previously the only US Food and Drug Administration (FDA) approved
oral diabetic agent for the pediatric population. Providers should start with 500 to 1000 mg daily
for 7 to 15 days and titrate the dose up once a week over a period of 3 to 4 weeks, depending on
the patient’s tolerance. The maximum dose is 1000 mg twice a day (Zeitler et al., 2018). Patients
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that have a HbA1c greater than 8.5%, with no acidosis, and with or without ketosis should be
started on both metformin and insulin. Insulin should start at 0.25 to 0.5 units/kg and can be
titrated up to a maximum of 1.5 units/kg. If optimal glucose levels are not met with both
metformin and insulin therapy, additional medication may be considered. Liraglutide, a
glucagon-like peptide-1 receptor agonist, was recently approved for use in children 10 years of
age and older (FDA, 2019). The ADA (2020a) updated their recommendations to consider the
use of liraglutide if glycemic targets are not met with metformin and basal insulin, and there is
no family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Insulin can later be weaned if glycemic targets are continually met, and the child may
only need to take metformin. Patients and their families should be performing self-monitored
blood glucose (SMBG) at home in order to track glycemic levels and measure progress to goals.
Insulin should be weaned over a period of 2 to 6 weeks, and the dose should be decreased by 10
to 30% every few days (Zeitler et al., 2018). The goal of treatment should be a HbA1c less than
7.0%, and glycemic targets and the process of SMBG should be individualized (Panagiotopoulos
et al., 2018; Arslanian et al., 2018; ADA, 2020a).
Management
Once a diagnosis of T2DM has been made and initial treatment has been completed, it is
crucial that providers carefully manage the care of these patients. As in adults, T2DM is a
chronic condition, and excellent management requires participation from multiple disciplines.
Creating a multidisciplinary team including a primary provider, endocrinologist, social worker,
diabetic educator, dietician, school personnel, psychologist, and family members may be
beneficial and enable more effective long-term management (ADA, 2020a). Each discipline has
a specific role in managing a child with diabetes.
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It is essential that providers recommend intensive lifestyle changes with a focus on
weight loss, including increasing physical activity, and dietary measures. The ADA (2020a)
recommends a family lifestyle change involving the parents or caregivers in nutrition counseling,
incorporating physical activity, and understanding medical management (such as using insulin or
metformin) in order to successfully manage and guide the child. As youth with T2DM are
typically nearing or are of adolescence, they should be educated and encouraged to participate in
independent care; this includes SMBG, understanding appropriate dietary habits, participating in
daily physical activity, and knowing signs and symptoms of hypoglycemia or hyperglycemia.
Diabetic educators can be especially helpful in educating the patient and family in ways that are
easy for them to understand and retain the information and providing them with resources
(Galuska et al., 2018).
Dietary Changes
As most youth with T2DM are overweight or obese, weight loss should be the primary
focus of management. Dieticians who are knowledgeable about T2DM in youth should be
involved in nutrition counseling for these families. Recommendations include replacing sugary
beverages, such as soda or juice, with water and calorie-free beverages, increasing fruit and
vegetable intake, reducing consumption of processed or prepackaged foods, and exchanging high
caloric and high fat foods for more nutrient-dense, low-caloric options. Dietary interventions
should be family centered and everyone in the household should be making the same changes
together in order to encourage the patient to create and sustain healthy eating habits. Parents or
caregivers should also be educated on healthy diet choices and how to read nutrition labels.
Dieticians or diabetic educators should educate families in a culturally sensitive matter taking
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into account food preferences and providing appropriate options and/or substitutions (Xu &
Verre, 2018; Zeitler et al., 2018).
Physical Activity
Adding or increasing the amount of physical activity is another necessary lifestyle change
for young diabetics. Thirty to sixty minutes of moderate to vigorous activity daily is
recommended and can be split into multiple activities during the day (Arslanian et al., 2018;
Zeitler et al., 2018). Families should be involved in this lifestyle change as well, with at least one
family member available to participate in the activity with the child and provide encouragement.
Activities such as taking the stairs instead of the elevator, parking far from a store entrance to
increase walking, walking to school or the store if nearby, or doing household chores or yard
work are ways to incorporate more daily physical activity. Screen time should also be kept to a
two-hour minimum to decrease sedentary lifestyle (Zeitler et al., 2018).
Psychosocial Factors
Racial or ethnic minority groups account for the majority of youth with T2DM (Hamman
et al., 2014; Mayer-Davis et al., 2017). Providers should recognize potential social issues and
understand that finances, housing or living conditions, food instability, limited access to services,
or cultural barriers may cause difficulties in management for the patient and family (ADA,
2020a; Arslanian et al., 2018). Providers should be sensitive to these stressors and personalize
care while providing appropriate resources. Social workers are an important part of the
multidisciplinary team and can provide additional assistance and resources to the family.
Providers should also assess the patient’s psychosocial status. The diagnosis of T2DM
leads to some overwhelming lifestyle changes for a family, and especially for the patient.
Adolescents with T2DM reported more feelings of depression and a lower quality of life when
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compared to those with T1DM (Hood et al., 2014). Assessing the patient’s coping skills and
mental health is another necessary component for proper management; psychologists may also
be part of the multidisciplinary team for further evaluation and additional help.
In addition to socioeconomic or environmental stressors, most of the youth with T2DM
are adolescents and may have additional stressors. Adolescents in particular are subject to
increased social or psychological stressors that may increase participation in risky behaviors such
as tobacco or alcohol use or unprotected sex. Individuals should be counseled on smoking and
alcohol use, and females should be educated on contraceptive use to avoid pregnancy (Zeitler et
al., 2018).
Complications
While metformin is the appropriate pharmacological treatment for T2DM, the TODAY
study found that glycemic control was maintained for only about half of the patients on
metformin monotherapy. This suggests that T2DM in youth is much more aggressive and can
lead to the development of complications early on, if not properly managed (Narasimhan &
Weinstock, 2014). Potential complications include nephropathy, neuropathy, retinopathy, nonalcoholic fatty liver disease (NAFLD), obstructive sleep apnea (OSA), polycystic ovary
syndrome (POS), cardiovascular disease, and dyslipidemia. Some of these conditions may be
present at diagnosis. The ADA (2020a) recommends obtaining blood pressure measurements, a
fasting lipid panel, liver enzyme panel, and urine albumin to creatinine ratio (ACR) at the time of
diagnosis. A dilated eye exam and foot exam should also be performed at the time of diagnosis
or soon after (ADA, 2020a).
Blood pressure (BP) should be measured at each visit and should not be greater than the
90th percentile for age, sex, and height. Lifestyle interventions to lose weight should be
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encouraged for adolescents aged 13 years and older with a BP greater than 120/80 mmHg. If
there is no change with intervention after 6 months, antihypertensive therapy should be started
with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ADA, 2020a).
Desired levels of lipids for children and adolescents are as follows: low density lipid
(LDL) cholesterol less than 100 mg/dL, high density lipid cholesterol greater than 35 mg/dL, and
triglycerides less than 150 mg/dL. Measures for controlling lipid levels should focus on blood
glucose control and dietary measures. If LDL remains above the target goal after 6 months of
lifestyle interventions, statin therapy should be started. If lipids are at goal, they should be
checked annually (ADA, 2020a).
Albuminuria may be present for many adolescents at the time of diagnosis. In the
TODAY study (2013), 6.3% of youth had microalbuminuria at baseline, but this number rose to
16.6% after follow-up at the end of the study. An elevated urine ACR should be obtained at
diagnosis and confirmed with two out of three samples. Estimated glomerular filtration rate
(GFR) should also be obtained at time of diagnosis. Providers should monitor kidney function
and recheck urine ACR and estimated GFR in pediatric patients annually (ADA, 2020a).
A dilated eye exam should be performed at the time of diagnosis or as soon as possible to
evaluate for retinopathy. Comprehensive foot examinations with monofilaments should also be
performed to assess for neuropathy. Screening for retinopathy and neuropathy should be
completed annually, and prevention for both retinopathy and neuropathy involve optimizing
blood glucose levels (ADA, 2020a).
Lastly, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) should be
obtained at the time of diagnosis to evaluate for NAFLD and non-alcoholic steatohepatitis.
Weight loss can improve these conditions; however, persistently elevated liver enzymes may
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warrant a referral to a gastroenterologist. An ALT and AST should also be obtained annually
(ADA, 2020a).
Future Implications
Pediatric diabetes continues to be a growing issue. As T2DM continues to increase in
youth, providers should be knowledgeable about evidence-based screening, diagnosis, and
management. Distinguishing between diabetes phenotypes can be difficult, but providers should
be thorough in their assessments in order to start appropriate treatment. The foundation of
treatment and management should be based on lifestyle changes to promote weight loss and
healthy habits. Proactively involving the family in intensive lifestyle changes can improve
chances for achieving optimal glucose levels and proper management early on to help prevent
long term complications. Adolescents should be encouraged to be independent in their diabetes
management in order to be successful during the transition to young adulthood. Care should
always be individualized, culturally sensitive, and involve multidisciplinary team members.
While the amount of information and research on pediatric diabetes continues to increase, future
studies should continue to explore ways to prevent or reduce the risks and complications of
developing T2DM, including any lifestyle and pharmacological interventions that may best treat
and manage this special population.
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